Literature DB >> 25636576

β-Glucan enhances cytotoxic T lymphocyte responses by activation of human monocyte-derived dendritic cells via the PI3K/AKT pathway.

Jun Ding1, Tongbao Feng2, Yongling Ning2, Wenjing Li2, Qiyong Wu3, Keqing Qian2, Yong Wang1, Chunjian Qi4.   

Abstract

PURPOSE: To investigate the effects of β-(1,3/1,6)-d-glucan on dendritic cells (DCs) maturation, cytotoxic T lymphocyte responses and the molecular mechanisms of its transition. METHODS AND
RESULTS: Human monocyte-derived DCs were matured using yeast-derived particulate β-glucan (WGP) or a mix of TNF-α, IL-1β and IL-6 ("Conv mix"). Multicolor flow cytometry was used to study the DCs phenotype and cytotoxic T-lymphocyte priming and differentiation. ELISA and RT-PCR assays were used to evaluate cytokine production. Western blot was used to investigate the signal pathways. WGP-matured DCs functions were compared with those of Conv mix-matured DCs. WGP-matured DCs expressed higher levels of CD11c, CD86, CD40 and HLA-DR; produced higher levels of pro-inflammatory cytokines; and elicited more CTL priming and differentiation than Conv mix-matured DCs. The PI3K/AKT signaling pathway was involved in WGP-induced dendritic cell maturation. Furthermore, WGP-matured DCs significantly increased tumor-specific CTL responses.
CONCLUSION: Excellent ability of yeast-derived particulate β-glucan to induce DCs maturation and tumor-specific CTL responses explains, in part, its clinical benefits and emphasizes its utility in ex vivo maturation of DCs generated for therapy.
Copyright © 2015 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dendritic cells; Immune response; Signal pathway; β-Glucan

Mesh:

Substances:

Year:  2015        PMID: 25636576     DOI: 10.1016/j.humimm.2015.01.009

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  8 in total

1.  Curdlan blocks the immune suppression by myeloid-derived suppressor cells and reduces tumor burden.

Authors:  Ke Rui; Jie Tian; Xinyi Tang; Jie Ma; Ping Xu; Xinyu Tian; Yungang Wang; Huaxi Xu; Liwei Lu; Shengjun Wang
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

2.  β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer.

Authors:  Mengjie Wang; Yu Bai; Jiaxin Pei; Dongqing Li; Xiaolin Pu; Wenyu Zhu; Lei Xia; Chunjian Qi; Hua Jiang; Yongling Ning
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

3.  HMGB1/PI3K/Akt/mTOR Signaling Participates in the Pathological Process of Acute Lung Injury by Regulating the Maturation and Function of Dendritic Cells.

Authors:  Ruiting Li; Xiaojing Zou; Haiyan Huang; Yuan Yu; Hongmei Zhang; Pei Liu; Shangwen Pan; Yaqi Ouyang; You Shang
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

Review 4.  Shaping the Innate Immune Response by Dietary Glucans: Any Role in the Control of Cancer?

Authors:  Manuela Del Cornò; Sandra Gessani; Lucia Conti
Journal:  Cancers (Basel)       Date:  2020-01-08       Impact factor: 6.639

Review 5.  Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review.

Authors:  Valeria Cognigni; Nicoletta Ranallo; Francesca Tronconi; Francesca Morgese; Rossana Berardi
Journal:  Explor Target Antitumor Ther       Date:  2021-04-30

Review 6.  An important polysaccharide from fermentum.

Authors:  Bobo Lin; Gangliang Huang
Journal:  Food Chem X       Date:  2022-07-08

7.  Syk-dependent glycolytic reprogramming in dendritic cells regulates IL-1β production to β-glucan ligands in a TLR-independent manner.

Authors:  Phyu M Thwe; Daniel I Fritz; Julia P Snyder; Portia R Smith; Kylie D Curtis; Alexandra O'Donnell; Nicholas A Galasso; Leslie A Sepaniac; Benjamin J Adamik; Laura R Hoyt; Princess D Rodriguez; Tyler C Hogan; Andrea F Schmidt; Matthew E Poynter; Eyal Amiel
Journal:  J Leukoc Biol       Date:  2019-09-11       Impact factor: 4.962

8.  What is the effectiveness of beta-glucan for treatment of acute otitis media?

Authors:  Erdem Atalay Cetinkaya; Osman Ciftci; Saadet Alan; Mustafa Namık Oztanır; Nese Basak
Journal:  Braz J Otorhinolaryngol       Date:  2020-03-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.